Sugi Predict

Sugi Predict / Compounds / SCHEMBL4470826

SCHEMBL4470826

SCHEMBL4470826

Cc1cc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)ccc1Br

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 10/20 0.83
▸ AXL P30530 8/20 0.83
▸ CLK4 Q9HAZ1 7/20 0.83
▸ HIPK4 Q8NE63 7/20 0.83
▸ PLK4 O00444 7/20 0.83
▸ MAP4K4 O95819 7/20 0.83
▸ MARK3 P27448 7/20 0.83
▸ MAP4K2 Q12851 7/20 0.83
▸ STK3 Q13188 7/20 0.83
▸ SLK Q9H2G2 7/20 0.83
▸ MKNK2 Q9HBH9 7/20 0.83
▸ LCK P06239 7/20 0.83
▸ CSF1R P07333 6/20 0.83
▸ AURKA O14965 6/20 0.83
▸ BLK P51451 6/20 0.83
▸ LIMK1 P53667 6/20 0.83
▸ CSNK1G2 P78368 6/20 0.83
▸ CAMK2G Q13555 6/20 0.83
▸ CAMK2D Q13557 6/20 0.83
▸ MARK2 Q7KZI7 6/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4472667 0.91 KIT (1.00) KITAXLCLK4HIPK4PLK4
SCHEMBL4485677 0.88 KDR (0.76) KITAXLCLK4HIPK4PLK4
SCHEMBL4471506 0.85 KDR (0.83) KITAXLCLK4HIPK4PLK4
SCHEMBL4478814 0.85 KDR (0.78) KITAXLCLK4HIPK4PLK4
SCHEMBL232042 0.85 KDR (1.00) KITAXLCLK4HIPK4PLK4
SCHEMBL3527316 0.84 KDR (0.83) KITAXLCLK4HIPK4PLK4
SCHEMBL4486611 0.83 KDR (1.00) KITAXLCLK4HIPK4PLK4
SCHEMBL4463123 0.82 KDR (0.67) KITAXLCLK4HIPK4PLK4
SCHEMBL4477490 0.82 KDR (0.81) KITAXLCLK4HIPK4PLK4
SCHEMBL4474877 0.82 KDR (0.80) KITAXLCLK4HIPK4PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487841-B1 THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS ABBVIE INC (US) 2014-01-15 — — EP disclosed
US-7560552-B2 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES (US) 2009-07-14 — — US disclosed
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors MICHAELIDES MICHAEL R 2006-12-07 — — US disclosed
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBVIE INC. 2004-01-22 — — US disclosed
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KIT 394/4885AXL 510/4885CLK4 1081/4885
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors ABL1, LCK, ERBB2 KIT 361/4885AXL 424/4885CLK4 935/4885
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KIT 394/4885AXL 510/4885CLK4 1081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.